Timing note: Bunge is scheduled to release results today, Wednesday, July 29, 2026, before the market opens, followed by its conference call at 8:00 a.m. Eastern / 7:00 a.m. Central. The date in the prompt is correct, but it is today rather than tomorrow. (investors.bunge.com)
The most important issue is not whether Bunge beats the quarterly consensus by a few cents. It is whether management can sustain or increase its $9.00–$9.50 full-year adjusted EPS outlook after a stronger-than-expected first quarter.
The Street expects approximately:
| Metric | Q2 2026 consensus |
|---|---|
| Adjusted EPS | $1.97 |
| Revenue | $22.81 billion |
| Q2 2025 adjusted EPS | $1.31 |
Consensus figures vary slightly by provider—another estimate is $1.95 and $22.58 billion—but the general bar is clear. (marketbeat.com)
The key setup is that $1.97 is already the top of Bunge’s implied Q2 range. At the Q1 call, management said it expected approximately 40% of full-year earnings in the first half. Applying that to the $9.00–$9.50 outlook and subtracting Q1’s $1.83 produces implied Q2 adjusted EPS of roughly $1.77–$1.97. Thus, an in-line quarter would still represent execution at the upper end of the company’s prior cadence.
This will be the first second-quarter report fully incorporating Viterra; the transaction closed on July 2, 2025, immediately after last year’s second quarter. Reported year-over-year revenue and volume growth will therefore be dominated by the enlarged company rather than organic growth. (investors.bunge.com)
Investors should place more weight on:
Reported GAAP EPS could again be noisy. In Q1, Bunge reported GAAP EPS of only $0.35 but adjusted EPS of $1.83, primarily because of temporary commodity, freight and foreign-exchange mark-to-market timing effects. (investors.bunge.com)
Bunge’s Q1 adjusted EPS of $1.83 significantly exceeded expectations and prompted management to raise full-year guidance from $7.50–$8.00 to $9.00–$9.50. Adjusted segment EBIT rose to $661 million from $406 million, led by Soybean Processing and Refining and Softseed Processing and Refining. (investors.bunge.com)
The quarter benefited from:
But management repeatedly cautioned that forward processing curves were inverted and visibility into the second half was limited. Q2 should indicate whether Q1 was primarily an unusually favorable first-half event or the beginning of a more durable improvement in Bunge’s earnings power.
This segment produced $377 million of adjusted EBIT in Q1, up from $241 million a year earlier. Soybean processing volumes increased to 10.8 million metric tons, helped by the combined company’s larger Argentine footprint, while merchandising volumes more than doubled. (investors.bunge.com)
What to watch:
A healthy result should demonstrate that the earnings strength is coming from several parts of the value chain—origination, processing, oil merchandising and refining—rather than from one temporary margin spike.
Q1 adjusted EBIT was $195 million, more than double the prior-year figure. Bunge cited better performance in Argentina, North America and Europe, along with increased origination in Canada and Australia. (investors.bunge.com)
Key variables include:
Management previously indicated that average softseed curves had improved, particularly in North America, but European margins remained dependent on a better new crop.
Grain was Q1’s weak point. Adjusted EBIT declined to $44 million from $60 million, with higher wheat milling, cotton and commercial-services earnings offset by poor ocean-freight results following a spike in bunker-fuel costs. (investors.bunge.com)
A sequential recovery would be encouraging, but this remains Bunge’s least predictable segment. Investors should listen for:
This segment is also where many of the less easily quantified Viterra commercial synergies should eventually appear.
Management lowered its full-year expectations for this segment after Q1, citing softer food-customer volumes, weaker cocoa-butter-equivalent margins, tariff uncertainty and customers remaining shorter-bought.
The bar is therefore lower, but investors will want to see that weakness is contained. Updates on the newly acquired IFF soy-protein assets and the commissioning of the Morristown soy-protein facility would help reinforce the longer-term specialty-ingredients story.
If Bunge reports the $1.97 consensus and maintains its $9.00–$9.50 guidance, it would need to earn approximately $5.20–$5.70 in the second half.
Management previously indicated a roughly 45%/55% Q3/Q4 split within second-half earnings. Applied mechanically, that suggests:
That is a demanding, back-end-weighted profile. The market will therefore need convincing explanations around booked margins, forward curves, crop availability and synergy realization. Simply maintaining guidance without increased visibility could be viewed less favorably than maintaining guidance with evidence that more of the second-half earnings are contracted or operationally controlled.
At its March Investor Day, Bunge raised its expected annual cost synergies from the original $250 million target to approximately $350 million. Management also identified roughly $250–$300 million of commercial and network opportunities, although some of these are harder to measure quarter by quarter.
The company included about $190 million of cost synergies and $90 million of commercial synergies in its 2026 planning assumptions, and said in April that cost realization was running ahead of plan. Bunge also set a long-term objective of more than $15 of mid-cycle adjusted EPS by 2030, supported by synergies, projects, normalized margins and capital allocation. (investors.bunge.com)
Questions investors should want answered:
Q1 adjusted funds from operations were $530 million, while operating cash flow was negative because of working-capital movements. Bunge ended the quarter with adjusted leverage of 1.6 times and approximately $9.7 billion of unused committed credit facilities.
Management expects:
Higher commodity prices and a larger merchandising platform can consume substantial working capital even when underlying earnings are strong. Investors should distinguish between ordinary, readily marketable inventory financing and a deterioration in structural leverage. (investors.bunge.com)
BG closed July 28 at approximately $117.40, up about 32% year to date, but roughly 7% below its pre-Q1-report level and more than 10% below its early-June high.
At that price, the shares trade at approximately:
The long-term multiple looks inexpensive, but the $15 objective is a 2030 baseline rather than near-term guidance and depends on integration, projects, capital returns and normalized processing margins.
The consensus already assumes Bunge reaches the top of its prior implied Q2 earnings range, so a small EPS beat alone may not be enough. The more consequential signal will be whether management can defend—or raise—the $9.00–$9.50 outlook while demonstrating that the required second-half earnings are supported by processing economics, Viterra synergies and controllable execution.
The best result would combine solid oilseed earnings with a Grain recovery, accelerated synergies and firmer second-half visibility. The principal risk is that strong first-half biofuel and processing conditions fade before Bunge’s larger Viterra platform and growth projects fully translate into recurring earnings.